10-Q Filing

REGENERON PHARMACEUTICALS, INC. CIK: 872589 Q2 2018

Filing Information

Form Type	10-Q
Accession Number	`0001532176-18-000028`
Period End Date	20180630
Filing Date	20180802
Fiscal Year	2018
Fiscal Period	Q2
XBRL Instance	regn-20180630.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 63 Income Statement 76 Cash Flow Statement 54

Balance Sheet 63 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock, par value (in dollars per share)	`PreferredStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	30.00M	shares	Point-in-time
Preferred stock, shares authorized (in shares)	`PreferredStockSharesAuthorized`	30.00M	shares	Point-in-time
Preferred stock, issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, issued (in shares)	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, outstanding (in shares)	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$917.88M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$744.31M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$812.73M	USD	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$596.85M	USD	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$765.64M	USD	Point-in-time
Accounts receivable - trade, net	`AccountsReceivableNetCurrent`	$1.53B	USD	Point-in-time
Accounts receivable - trade, net	`AccountsReceivableNetCurrent`	$1.54B	USD	Point-in-time
Accounts receivable from Sanofi	`AccountsReceivableRelatedPartiesCurrent`	$243.24M	USD	Point-in-time
Accounts receivable from Sanofi	`AccountsReceivableRelatedPartiesCurrent`	$193.68M	USD	Point-in-time
Accounts receivable from Bayer	`AccountsAndNotesReceivableNet`	$242.01M	USD	Point-in-time
Treasury stock, outstanding (in shares)	`TreasuryStockShares`	3.76M	shares	Point-in-time
Accounts receivable from Bayer	`AccountsAndNotesReceivableNet`	$261.69M	USD	Point-in-time
Treasury stock, outstanding (in shares)	`TreasuryStockShares`	3.89M	shares	Point-in-time
Inventories	`InventoryNet`	$726.14M	USD	Point-in-time
Inventories	`InventoryNet`	$928.55M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$224.97M	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$163.60M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$4.34B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$4.81B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$1.49B	USD	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$2.04B	USD	Point-in-time
Property, plant, and equipment, net	`PropertyPlantAndEquipmentNet`	$2.46B	USD	Point-in-time
Property, plant, and equipment, net	`PropertyPlantAndEquipmentNet`	$2.36B	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$545.08M	USD	Point-in-time
Deferred tax assets	`DeferredIncomeTaxAssetsNet`	$506.29M	USD	Point-in-time
Other noncurrent assets	`OtherAssetsNoncurrent`	$85.67M	USD	Point-in-time
Other noncurrent assets	`OtherAssetsNoncurrent`	$77.87M	USD	Point-in-time
Total assets	`Assets`	$8.76B	USD	Point-in-time
Total assets	`Assets`	$9.95B	USD	Point-in-time
Accounts payable	`AccountsPayableCurrentAndNoncurrent`	$178.18M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrentAndNoncurrent`	$171.91M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesAndOtherLiabilities`	$637.16M	USD	Point-in-time
Accrued expenses and other current liabilities	`AccruedLiabilitiesAndOtherLiabilities`	$670.71M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.14B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.33B	USD	Point-in-time
Capital and facility lease obligations	`Capitalandfacilityleaseobligationsnoncurrent`	$705.90M	USD	Point-in-time
Capital and facility lease obligations	`Capitalandfacilityleaseobligationsnoncurrent`	$703.45M	USD	Point-in-time
Other noncurrent liabilities	`OtherLiabilitiesNoncurrent`	$190.02M	USD	Point-in-time
Other noncurrent liabilities	`OtherLiabilitiesNoncurrent`	$152.07M	USD	Point-in-time
Total liabilities	`Liabilities`	$2.62B	USD	Point-in-time
Total liabilities	`Liabilities`	$2.77B	USD	Point-in-time
Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none	`PreferredStockValue`	-	USD	Point-in-time
Preferred Stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding - none	`PreferredStockValue`	-	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$3.71B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$3.51B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$3.84B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$2.95B	USD	Point-in-time
Accumulated other comprehensive (loss) income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$640.00K	USD	Point-in-time
Accumulated other comprehensive (loss) income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-11.61M	USD	Point-in-time
Treasury Stock, at cost; 3,885,469 shares in 2018 and 3,763,868 shares in 2017	`TreasuryStockValue`	$353.85M	USD	Point-in-time
Treasury Stock, at cost; 3,885,469 shares in 2018 and 3,763,868 shares in 2017	`TreasuryStockValue`	$316.24M	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$7.19B	USD	Point-in-time
Total stockholders' equity	`StockholdersEquity`	$6.14B	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$9.95B	USD	Point-in-time
Total liabilities and stockholders' equity	`LiabilitiesAndStockholdersEquity`	$8.76B	USD	Point-in-time

Income Statement 76 line items

Line Item	Tag	Value	Unit	Period
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$2.79B	USD	2 Qtrs
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$1.47B	USD	1 Quarter
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$3.12B	USD	2 Qtrs
Revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$1.61B	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$509.98M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.03B	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpense`	$529.29M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.02B	USD	2 Qtrs
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$695.65M	USD	2 Qtrs
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$364.88M	USD	1 Quarter
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$306.91M	USD	1 Quarter
Selling, general, and administrative	`SellingGeneralAndAdministrativeExpense`	$603.75M	USD	2 Qtrs
Total expenses	`CostsAndExpenses`	$1.81B	USD	2 Qtrs
Total expenses	`CostsAndExpenses`	$919.80M	USD	1 Quarter
Total expenses	`CostsAndExpenses`	$985.83M	USD	1 Quarter
Total expenses	`CostsAndExpenses`	$1.93B	USD	2 Qtrs
Income from operations	`OperatingIncomeLoss`	$980.85M	USD	2 Qtrs
Income from operations	`OperatingIncomeLoss`	$550.31M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$622.19M	USD	1 Quarter
Income from operations	`OperatingIncomeLoss`	$1.19B	USD	2 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-19.06M	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$40.80M	USD	1 Quarter
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$65.41M	USD	2 Qtrs
Other income (expense), net	`OtherNonoperatingIncomeExpense`	$-9.81M	USD	2 Qtrs
Interest expense	`InterestExpense`	$6.92M	USD	1 Quarter
Interest expense	`InterestExpense`	$5.40M	USD	1 Quarter
Interest expense	`InterestExpense`	$12.90M	USD	2 Qtrs
Interest expense	`InterestExpense`	$13.36M	USD	2 Qtrs
Total other income (expense)	`NonoperatingIncomeExpense`	$-22.71M	USD	2 Qtrs
Total other income (expense)	`NonoperatingIncomeExpense`	$-24.46M	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$33.89M	USD	1 Quarter
Total other income (expense)	`NonoperatingIncomeExpense`	$52.05M	USD	2 Qtrs
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$656.07M	USD	1 Quarter
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$525.85M	USD	1 Quarter
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$1.24B	USD	2 Qtrs
Income before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$958.14M	USD	2 Qtrs
Income tax expense	`IncomeTaxExpenseBenefit`	$104.66M	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$212.08M	USD	2 Qtrs
Income tax expense	`IncomeTaxExpenseBenefit`	$138.11M	USD	1 Quarter
Income tax expense	`IncomeTaxExpenseBenefit`	$321.46M	USD	2 Qtrs
Net income	`NetIncomeLoss`	$551.41M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.03B	USD	2 Qtrs
Net income	`NetIncomeLoss`	$387.74M	USD	1 Quarter
Net income	`NetIncomeLoss`	$636.67M	USD	2 Qtrs
Net income per share - basic (in dollars per share)	`EarningsPerShareBasic`	$9.56	USD	2 Qtrs
Net income per share - basic (in dollars per share)	`EarningsPerShareBasic`	$5.12	USD	1 Quarter
Net income per share - basic (in dollars per share)	`EarningsPerShareBasic`	$6.02	USD	2 Qtrs
Net income per share - basic (in dollars per share)	`EarningsPerShareBasic`	$3.66	USD	1 Quarter
Net income per share - diluted (in dollars per share)	`EarningsPerShareDiluted`	$3.34	USD	1 Quarter
Net income per share - diluted (in dollars per share)	`EarningsPerShareDiluted`	$8.97	USD	2 Qtrs
Net income per share - diluted (in dollars per share)	`EarningsPerShareDiluted`	$4.82	USD	1 Quarter
Net income per share - diluted (in dollars per share)	`EarningsPerShareDiluted`	$5.51	USD	2 Qtrs
Weighted average shares outstanding - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	107.72M	shares	2 Qtrs
Weighted average shares outstanding - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	105.80M	shares	2 Qtrs
Weighted average shares outstanding - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	107.80M	shares	1 Quarter
Weighted average shares outstanding - basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	106.03M	shares	1 Quarter
Weighted average shares - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	115.61M	shares	2 Qtrs
Weighted average shares - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	114.48M	shares	1 Quarter
Weighted average shares - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	114.70M	shares	2 Qtrs
Weighted average shares - diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	116.14M	shares	1 Quarter
Net income	`NetIncomeLoss`	$551.41M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.03B	USD	2 Qtrs
Net income	`NetIncomeLoss`	$387.74M	USD	1 Quarter
Net income	`NetIncomeLoss`	$636.67M	USD	2 Qtrs
Unrealized gain (loss) on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$15.16M	USD	2 Qtrs
Unrealized gain (loss) on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$3.37M	USD	1 Quarter
Unrealized gain (loss) on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$8.20M	USD	1 Quarter
Unrealized gain (loss) on marketable securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-7.71M	USD	2 Qtrs
Unrealized gain on cash flow hedges	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	$608.00K	USD	1 Quarter
Unrealized gain on cash flow hedges	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	$28.00K	USD	2 Qtrs
Unrealized gain on cash flow hedges	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	$2.05M	USD	2 Qtrs
Unrealized gain on cash flow hedges	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax`	$28.00K	USD	1 Quarter
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$1.02B	USD	2 Qtrs
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$651.86M	USD	2 Qtrs
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$555.39M	USD	1 Quarter
Comprehensive income	`ComprehensiveIncomeNetOfTax`	$395.98M	USD	1 Quarter

Cash Flow Statement 54 line items

Line Item	Tag	Value	Unit	Period
Net income	`NetIncomeLoss`	$551.41M	USD	1 Quarter
Net income	`NetIncomeLoss`	$1.03B	USD	2 Qtrs
Net income	`NetIncomeLoss`	$387.74M	USD	1 Quarter
Net income	`NetIncomeLoss`	$636.67M	USD	2 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$70.00M	USD	2 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$73.24M	USD	2 Qtrs
Non-cash compensation expense	`ShareBasedCompensation`	$255.05M	USD	2 Qtrs
Non-cash compensation expense	`ShareBasedCompensation`	$189.22M	USD	2 Qtrs
Other non-cash items, net	`OtherNoncashIncomeExpense`	$54.98M	USD	2 Qtrs
Other non-cash items, net	`OtherNoncashIncomeExpense`	$-37.63M	USD	2 Qtrs
Deferred taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$57.74M	USD	2 Qtrs
Deferred taxes	`IncreaseDecreaseInDeferredIncomeTaxes`	$15.49M	USD	2 Qtrs
Increase in Sanofi, Bayer, and trade accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$232.93M	USD	2 Qtrs
Increase in Sanofi, Bayer, and trade accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$64.91M	USD	2 Qtrs
Increase in inventories	`IncreaseDecreaseInInventories`	$151.54M	USD	2 Qtrs
Increase in inventories	`IncreaseDecreaseInInventories`	$182.10M	USD	2 Qtrs
Decrease (increase) in prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$77.17M	USD	2 Qtrs
Decrease (increase) in prepaid expenses and other assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-59.43M	USD	2 Qtrs
Increase (decrease) in deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-10.65M	USD	2 Qtrs
Increase (decrease) in deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-84.24M	USD	2 Qtrs
Increase (decrease) in accounts payable, accrued expenses, and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$66.98M	USD	2 Qtrs
Increase (decrease) in accounts payable, accrued expenses, and other liabilities	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-147.23M	USD	2 Qtrs
Total adjustments	`AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$-16.08M	USD	2 Qtrs
Total adjustments	`AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities`	$-311.34M	USD	2 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$1.01B	USD	2 Qtrs
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$325.33M	USD	2 Qtrs
Purchases of marketable and other securities	`PaymentsToAcquireMarketableSecurities`	$477.41M	USD	2 Qtrs
Purchases of marketable and other securities	`PaymentsToAcquireMarketableSecurities`	$1.18B	USD	2 Qtrs
Sales or maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$462.21M	USD	2 Qtrs
Sales or maturities of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$272.17M	USD	2 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$105.31M	USD	2 Qtrs
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$191.39M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-310.55M	USD	2 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-910.38M	USD	2 Qtrs
Proceeds in connection with capital and facility lease obligations	`ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities`	$57.00M	USD	2 Qtrs
Proceeds in connection with capital and facility lease obligations	`ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities`	-	USD	2 Qtrs
Payments in connection with capital and facility lease obligations	`RepaymentsOfLongTermDebtAndCapitalSecurities`	-	USD	2 Qtrs
Payments in connection with capital and facility lease obligations	`RepaymentsOfLongTermDebtAndCapitalSecurities`	$19.93M	USD	2 Qtrs
Proceeds from issuance of Common Stock	`ProceedsFromIssuanceOfCommonStock`	$34.07M	USD	2 Qtrs
Proceeds from issuance of Common Stock	`ProceedsFromIssuanceOfCommonStock`	$188.69M	USD	2 Qtrs
Payments in connection with Common Stock tendered for employee tax obligations	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$31.44M	USD	2 Qtrs
Payments in connection with Common Stock tendered for employee tax obligations	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$31.85M	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$194.33M	USD	2 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$2.22M	USD	2 Qtrs
Net increase in cash, cash equivalents, and restricted cash	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$209.11M	USD	2 Qtrs
Net increase in cash, cash equivalents, and restricted cash	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$105.14M	USD	2 Qtrs
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$825.23M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$930.38M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$756.81M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$547.70M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$825.23M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$930.38M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$756.81M	USD	Point-in-time
Cash, cash equivalents, and restricted cash at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$547.70M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.